Edwards Lifesciences Co. (NYSE:EW) VP Sells $34,380.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Edwards Lifesciences Stock Performance

Shares of EW traded down $0.41 during mid-day trading on Thursday, reaching $69.87. The company had a trading volume of 5,723,046 shares, compared to its average volume of 4,149,974. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market capitalization of $41.21 billion, a P/E ratio of 10.08, a PEG ratio of 3.77 and a beta of 1.11. The stock has a 50 day moving average of $71.91 and a two-hundred day moving average of $71.61. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.59 EPS. On average, analysts expect that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Institutional Trading of Edwards Lifesciences

A number of institutional investors and hedge funds have recently made changes to their positions in EW. FSA Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the third quarter worth $30,000. Prospera Private Wealth LLC purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Peoples Bank KS purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $40,000. Finally, Roble Belko & Company Inc acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $46,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Truist Financial restated a “hold” rating and issued a $78.00 price objective (up from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. JPMorgan Chase & Co. increased their price objective on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Wolfe Research downgraded Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a report on Thursday. Finally, Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.